A Review of the Therapeutic Potential of Ginseng and Its Bioactive Components in Nonalcoholic Fatty Liver Disease by Hao L, Li S, Li C, Zhang Z, Hu X, Yan H

“…In recent years, ginseng and its principal active components, such as ginsenosides, have shown potential protective effects in the treatment of these liver diseases. In NAFLD, studies have demonstrated that ginseng can improve hepatic lipid metabolism, reduce inflammatory responses, and inhibit oxidative stress and fibrosis, thereby attenuating the progression of NAFLD. …”
Get full text

Long-Term Effects of Metformin and Lifestyle Modification on Nonalcoholic Fatty Liver Disease Obese Adolescents by Lian Tock, Ana R. Dâmaso, Aline de Piano, June Carnier, Priscila L. Sanches, Henrique Manoel Lederman, Regina M. Y. Ernandes, Marco Túlio de Mello, Sérgio Tufik

Get full text

SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases by Minoru Fujimoto, Tetsuji Naka

“…Thus, SOCS1 and other SOCS proteins are potential targets for the therapy of human liver diseases.…”
Get full text

Elevated Bile Acids Induce Circadian Rhythm Sleep Disorders in Chronic Liver DiseasesSummary by Lan Zhou, Min Yan, Qin Luo, Wen Qiu, Yu-Ru Guo, Xiao-Qing Guo, Hong-Bin Yu, Jing-Ru Huo, Yan-Lin Feng, De-Ping Wang, Teng Sun, Kai-Fang Wang, Jian-Yun Shi, Xuan Shang, Mei-Na Wu, Lin Wang, Ji-Min Cao

Subjects: Get full text

Liver regeneration in fatty liver disease: can metabolomics shed light on the contribution of the gut microbiome? by Florian Jokisch, Laura Jennifer Marie Geyer, Klaus-Peter Janssen

Get full text

Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity by Jae Hyun Bae, Young Min Cho

Get full text

Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society by V. T. Ivashkin, M. V. Mayevskaya, Ch. S. Pavlov, Yu. P. Sivolap, V. D. Lunkov, M. S. Zharkova, R. V. Maslennikov

“…To present clinical guidelines of the Russian Scientific Liver Society on diagnosis and treatment of alcoholic liver disease to general practitioners. Summary. Harmful alcohol intake is the burning issue for Russia. …”
Get full text

Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study by Steven Dooley, Juan Du, Xiaoping Tang, Lan Chen, Jinzhu Jia, Fujun Li, Yanyan Shi, Christoph Meyer, Zhongwei Zhu, Yanming Zhang, Roman Liebe, Keming Hu, Tingting Zhou, Huier Zhang, Hong-Lei Weng, Tong Huang

“…Eleven years of NAFLD are not sufficient to cause severe liver disease. Age and obesity are direct risk factors for NAFLD. …”
Get full text

Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus by Lung-Wen Tsai, Yi-Hsiang Lu, Rajni Dubey, Jeng-Fong Chiou

“…Clinically, it has also been revealed that the existence of nonalcoholic fatty liver disease (NAFLD) enhances the incidence of type 2 diabetes mellitus (T2DM), while T2DM exacerbates NAFLD to extremely severe forms of steatohepatitis, cirrhosis, and hepatocellular carcinoma. …”
Get full text

Insulin Resistance Markers to Detect Nonalcoholic Fatty Liver Disease in a Male Hispanic Population by Maritza Pérez-Mayorga, Jose P. Lopez-Lopez, Maria A. Chacon-Manosalva, Maria G Castillo, Johanna Otero, Daniel Martinez-Bello, Diego Gomez-Arbelaez, Daniel D. Cohen, Patricio Lopez-Jaramillo

“…Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver disease and is closely associated with cardiometabolic disorders, being insulin resistance (IR) the common pathogenic mechanism. …”
Get full text

The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background by Jinsheng Yu, Sharon Marsh, Junbo Hu, Wenke Feng, Chaodong Wu

“…Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and it comprises a spectrum of hepatic abnormalities from simple hepatic steatosis to steatohepatitis, fibrosis, cirrhosis, and liver cancer. …”
Get full text

Frailty and Sarcopenia Assessment in Patients with Advanced Chronic Liver Disease in a Tertiary Center in Romania by Petruta Violeta Filip, Denisa Cuciureanu, Corina Silvia Pop, Andreea Nicoleta Marinescu, Florentina Furtunescu, Laura Sorina Diaconu

Subjects: “…advance chronic liver disease…”
Get full text

Implication of Nonalcoholic Fatty Liver Disease, Metabolic Syndrome, and Subclinical Inflammation on Mild Renal Insufficiency by Ga Eun Nam, Soon Young Hwang, Hye Soo Chung, Ju Hee Choi, Hyun Jung Lee, Nam Hoon Kim, Hye Jin Yoo, Ji-A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi

“…Limited information exists about the impact of nonalcoholic fatty liver disease (NAFLD) on mild renal insufficiency. We compared the relative influence of NAFLD, metabolic syndrome (MetS), and subclinical inflammation, alone or in combination, on mild renal insufficiency. …”
Get full text

Age-related features of the pattern of oral fluid patients with non-alcoholic fatty liver disease by Nataliya Emelyanova, Dmitry Emelyanov

“…Aims: To study the age-related features of oral fluid facies in patients with non-alcoholic fatty liver disease. Materials and methods: Sixty-one patients with non-alcoholic fatty liver disease and 57 somatically healthy patients were selected for study. …”
Get full text

High serum N-terminal propeptide of procollagen type III concentration is associated with liver diseases by Monika Gudowska, Ewa Gruszewska, Anatol Panasiuk, Bogdan Cylwik, Magdalena Swiderska, Robert Flisiak, Maciej Szmitkowski, Lech Chrostek

“…Aim : To evaluate the effect of liver diseases of different aetiologies and clinical severity of liver cirrhosis on the serum level of PIIINP. …”
Get full text

Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis by Wenxia Lu, Sainan Li, Jingjing Li, Jianrong Wang, Rong Zhang, Yuqing Zhou, Qin Yin, Yuanyuan Zheng, Fan Wang, Yujing Xia, Kan Chen, Tong Liu, Jie Lu, Yingqun Zhou, Chuanyong Guo

“…A meta-analysis was conducted to assess the effect of omega-3 fatty acid supplementation (n-3 PUFAs) in lowering liver fat, liver enzyme (alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) levels), and blood lipids (triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), and low density lipoprotein (LDL)) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). …”
Get full text

Exome sequencing reveals IFT172 variants in patients with non-syndromic cholestatic liver disease. by Magdaléna Neřoldová, Elżbieta Ciara, Janka Slatinská, Soňa Fraňková, Petra Lišková, Radana Kotalová, Janka Globinovská, Markéta Šafaříková, Lucie Pfeiferová, Hana Zůnová, Lenka Mrázová, Viktor Stránecký, Alena Vrbacká, Ondřej Fabián, Eva Sticová, Daniela Skanderová, Jan Šperl, Marta Kalousová, Tomáš Zima, Milan Macek, Joanna Pawlowska, A S Knisely, Stanislav Kmoch, Milan Jirsa

“…<h4>Conclusion</h4>Our findings suggest association of IFT172 variants with non-syndromic cholestatic liver disease.…”
Get full text

Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice by Gilles Willemin, Catherine Roger, Armelle Bauduret, Kaori Minehira

“…However, it has never been addressed whether the MHC II pathway plays an important role in the development of nonalcoholic fatty liver disease, the most common form of liver disease. …”
Get full text

Hepatic Overexpression of GRP94 in a Rabbit Model of Parenteral Nutrition-Associated Liver Disease by Xueping Zhu, Xiaomin Zhang, Lingling Yu, Yumin Xu, Xing Feng, Jian Wang

“…To use a rabbit model of parenteral nutrition-associated liver disease (PNALD) to study changes of the endoplasmic reticulum stress (ERS) marker glucose regulatory protein 94 (GRP94) and determine its role in the pathogenesis of PNALD. …”
Get full text

The Role of the Microbiome and Intestinal Mucosal Barrier in the Development and Progression of Non-Alcoholic Fatty Liver Disease by T. S. Krolevets, M. A. Livzan, S. I. Mozgovoy

Subjects: “…non-alcoholic fatty liver disease…”
Get full text